Dermaxon
  • Home
  • About Us
    • Contact
  • News
  • Science
  • Our Technologies
    • The human brain
    • Skin
    • Pain
  • Pipeline
Select Page

Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.

Abstract: Inhibition of cytochrome P450 (CYP)-mediated retinoic acid (RA) metabolism by RA metabolism blocking agents (RAMBAs) increases endogenous retinoids and is an alternative to retinoid therapy. Currently available RAMBAs (i.e. liarozole and talarozole) tend to...
  • Facebook
  • RSS

Copyright, Dermaxon. All rights reserved.